Vision Failure Means End Of The Road For Oxurion
Executive Summary
Disappointing data from a trial of the last remaining drug in its pipeline means that the Belgium group formerly known as ThromboGenics is closing its doors after more than 30 years.
You may also be interested in...
Oxurion's Anti-PIGF Antibody Disappoints in Diabetic Macular Edema
The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.
ThromboGenics Eyes Name Change To Oxurion
With Jetrea being a disappointment on the commercial front, the Belgian biotech will hope that a new name will augur well for its pipeline of disease modifying compounds for diabetic eye disease.
Nordics BioPharma Sector In Rude Health Despite Global Downturn
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.